NVCR NovoCure Ltd
Nasdaq · SEC CIK 1645113 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $3.25M 20 sales by 14 insiders
- Filings on record
- 265 since 2021-07-08, latest 2026-07-01 16:33
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| Paravasthu Mukund | COO | — | $693.8K |
| Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| Brackmann Christoph | CFO | — | $85.3K |
| Stafford Kristin | Dir | — | $46.4K |
| Ocean Allyson J | Dir | — | $46.4K |
| Scannell Timothy J | Dir | — | $46.4K |
| VERNON W ANTHONY | Dir | — | $46.4K |
| Hung David | Dir | — | $46.4K |
Transactions 293
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-10-17 | 2022-10-13 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.01 | -6,754 | 43.6K | -13% | -$513.4K | |
| 2022-10-07 | 2022-10-06 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $84.37 | -6,754 | 50.4K | -12% | -$569.8K | |
| 2022-09-30 | 2022-09-29 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.35 | -6,754 | 57.1K | -11% | -$522.4K | |
| 2022-09-26 | 2022-09-22 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.00 | -6,754 | 63.9K | -10% | -$520.1K | |
| DM | 2022-09-19 | 2022-09-15 | NVCR | Leonard Frank X | Chief Development Off | S - Sale+OE | $88.52 | -12.3K | 70.6K | -15% | -$1.09M |
| D | 2022-09-19 | 2022-09-15 | NVCR | Leonard Frank X | Chief Development Off | M - OptEx | $7.15 | +5,517 | 82.9K | +7% | +$39.4K |
| A | 2022-09-13 | 2022-09-08 | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $81.48 | -6,754 | 77.4K | -8% | -$550.3K |
| 2022-09-12 | 2022-09-09 | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $88.00 | -1,863 | 84.2K | -2% | -$163.9K | |
| 2022-09-07 | 2022-09-06 | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $78.57 | -1,384 | 86.0K | -2% | -$108.7K | |
| 2022-09-06 | 2022-09-02 | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale | $79.04 | -269 | 83.2K | -0.3% | -$21.3K | |
| 2022-09-06 | 2022-09-02 | NVCR | Cordova Ashley | CFO | S - Sale | $79.04 | -885 | 72.4K | -1% | -$70.0K | |
| 2022-09-06 | 2022-09-02 | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $79.04 | -296 | 165.0K | -0.2% | -$23.4K | |
| 2022-09-06 | 2022-09-02 | NVCR | Burke William Patrick | CHRO | S - Sale | $79.04 | -718 | 55.5K | -1% | -$56.8K | |
| M | 2022-09-06 | 2022-09-01+ | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $77.50 | -14.8K | 88.8K | -14% | -$1.15M |
| M | 2022-08-04 | 2022-08-03 | NVCR | Benaim Ely | Chief Medical Off | S - Sale | $73.73 | -5,959 | 28.7K | -17% | -$439.3K |
| 2022-08-03 | 2022-08-02 | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $69.66 | -414 | 102.2K | -0.4% | -$28.8K | |
| 2022-08-03 | 2022-08-02 | NVCR | DOYLE WILLIAM F | Executive COB, Dir | S - Sale | $69.66 | -837 | 551.2K | -0.2% | -$58.3K | |
| 2022-08-03 | 2022-08-02 | NVCR | Cordova Ashley | CFO | A - Grant | $70.20 | +7,122 | 73.3K | +11% | +$500.0K | |
| 2022-08-03 | 2022-08-02 | NVCR | Benaim Ely | Chief Medical Off | S - Sale | $69.66 | -437 | 34.6K | -1% | -$30.4K | |
| 2022-07-07 | 2022-07-05 | NVCR | Ben Arye Barak | GC | A - Grant | $59.08 | +144 | 17.0K | +0.9% | +$8,508 | |
| 2022-07-07 | 2022-07-05 | NVCR | Benaim Ely | Chief Medical Off | A - Grant | $59.08 | +222 | 35.1K | +0.6% | +$13.1K | |
| 2022-07-07 | 2022-07-05 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $59.08 | +218 | 165.3K | +0.1% | +$12.9K | |
| 2022-07-07 | 2022-07-05 | NVCR | Weinberg Uri | CSO | A - Grant | $59.08 | +281 | 49.5K | +0.6% | +$16.6K | |
| 2022-07-07 | 2022-07-05 | NVCR | Burke William Patrick | CHRO | A - Grant | $59.08 | +213 | 56.2K | +0.4% | +$12.6K | |
| 2022-07-07 | 2022-07-05 | NVCR | Leonard Frank X | Chief Development Off | A - Grant | $59.08 | +312 | 102.6K | +0.3% | +$18.4K | |
| 2022-07-07 | 2022-07-05 | NVCR | Cordova Ashley | CFO | A - Grant | $59.08 | +251 | 66.1K | +0.4% | +$14.8K | |
| 2022-07-07 | 2022-07-05 | NVCR | Danziger Asaf | CEO, Dir | A - Grant | $59.08 | +276 | 13.6K | +2% | +$16.3K | |
| 2022-07-07 | 2022-07-05 | NVCR | Shah Pritesh | Chief Commercial Off | A - Grant | $59.08 | +312 | 83.5K | +0.4% | +$18.4K | |
| 2022-06-16 | 2022-06-10 | NVCR | HILLEMAN JERYL L | Dir | S - Sale | $69.61 | -407 | 2,537 | -14% | -$28.3K | |
| D | 2022-06-10 | 2022-06-08 | NVCR | Hung David | Dir | A - Grant | $0.00 | +2,427 | 9,141 | +36% | $0 |
| D | 2022-06-10 | 2022-06-08 | NVCR | LEUNG GABRIEL | Dir | A - Grant | $0.00 | +2,427 | 75.3K | +3% | $0 |
| M | 2022-05-12 | 2022-05-10+ | NVCR | Benaim Ely | Chief Medical Off | S - Sale | $63.17 | -4,205 | 34.8K | -11% | -$265.6K |
| D | 2022-03-11 | 2022-03-09 | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale+OE | $71.19 | -3,669 | 83.2K | -4% | -$261.2K |
| D | 2022-03-11 | 2021-07-31 | NVCR | Shah Pritesh | Chief Commercial Off | M - OptEx | $154.01 | +3,717 | 85.6K | +5% | +$572.5K |
| DM | 2022-03-11 | 2022-03-03 | NVCR | Cordova Ashley | CFO | M - OptEx | $14.61 | +5,040 | 64.7K | +8% | +$73.7K |
| 2022-03-09 | 2022-03-08 | NVCR | DOYLE WILLIAM F | Executive COB, Dir | S - Sale | $70.10 | -2,385 | 552.0K | -0.4% | -$167.2K | |
| 2022-03-09 | 2022-03-08 | NVCR | Burke William Patrick | CHRO | S - Sale | $70.10 | -1,037 | 56.0K | -2% | -$72.7K | |
| M | 2022-03-09 | 2022-03-07+ | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale | $69.73 | -7,775 | 84.4K | -8% | -$542.1K |
| 2022-03-09 | 2022-03-08 | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $70.10 | -744 | 102.3K | -0.7% | -$52.2K | |
| 2022-03-09 | 2022-03-08 | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $70.10 | -2,923 | 165.1K | -2% | -$204.9K | |
| 2022-03-09 | 2022-03-08 | NVCR | Longsworth Todd Christopher | GC | S - Sale | $70.10 | -2,339 | 62.5K | -4% | -$164.0K | |
| 2022-03-09 | 2022-03-08 | NVCR | Cordova Ashley | CFO | S - Sale | $70.10 | -759 | 60.8K | -1% | -$53.2K | |
| D | 2022-03-07 | 2022-03-03 | NVCR | Shah Pritesh | Chief Commercial Off | A - Grant | $0.00 | +21.7K | 95.2K | +30% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale | $72.54 | -5,543 | 89.7K | -6% | -$402.1K |
| D | 2022-03-07 | 2022-03-03 | NVCR | Weinberg Uri | CSO | A - Grant | $0.00 | +17.4K | 49.2K | +55% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | Longsworth Todd Christopher | GC | S - Sale | $71.87 | -3,067 | 66.8K | -4% | -$220.4K |
| D | 2022-03-07 | 2022-03-03 | NVCR | Leonard Frank X | Chief Development Off | A - Grant | $0.00 | +17.4K | 104.5K | +20% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $72.97 | -1,485 | 103.6K | -1% | -$108.4K |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | Benaim Ely | Chief Medical Off | S - Sale | $71.83 | -2,313 | 44.8K | -5% | -$166.1K |
| D | 2022-03-07 | 2022-03-03 | NVCR | Benaim Ely | Chief Medical Off | A - Grant | $0.00 | +17.4K | 45.6K | +62% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | Burke William Patrick | CHRO | S - Sale | $71.43 | -1,367 | 58.1K | -2% | -$97.6K |
| D | 2022-03-07 | 2022-03-03 | NVCR | Burke William Patrick | CHRO | A - Grant | $0.00 | +7,445 | 58.4K | +15% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $71.78 | -3,870 | 170.6K | -2% | -$277.8K |
| D | 2022-03-07 | 2022-03-03 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $0.00 | +21.9K | 171.9K | +15% | $0 |
| D | 2022-03-07 | 2022-03-03 | NVCR | Cordova Ashley | CFO | A - Grant | $0.00 | +21.5K | 63.3K | +51% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | Cordova Ashley | CFO | S - Sale | $73.17 | -1,705 | 61.6K | -3% | -$124.7K |
| 2022-01-12 | 2022-01-06 | NVCR | Burke William Patrick | CHRO | A - Grant | $63.82 | +80 | 51.0K | +0.2% | +$5,106 | |
| 2022-01-12 | 2022-01-06 | NVCR | Cordova Ashley | CFO | A - Grant | $63.82 | +46 | 41.8K | +0.1% | +$2,936 | |
| 2022-01-12 | 2022-01-06 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $63.82 | +75 | 150.0K | +0.1% | +$4,786 | |
| 2022-01-12 | 2022-01-06 | NVCR | Weinberg Uri | CSO | A - Grant | $63.82 | +35 | 31.8K | +0.1% | +$2,234 | |
| 2022-01-12 | 2022-01-06 | NVCR | Benaim Ely | Chief Medical Off | A - Grant | $63.82 | +55 | 28.2K | +0.2% | +$3,510 | |
| 2022-01-12 | 2022-01-06 | NVCR | Danziger Asaf | CEO, Dir | A - Grant | $63.82 | +31 | 13.3K | +0.2% | +$1,978 | |
| DM | 2022-01-05 | 2022-01-03 | NVCR | Burke William Patrick | CHRO | S - Sale+OE | $76.00 | -3,951 | 41.0K | -9% | -$300.3K |
| DM | 2022-01-05 | 2022-01-03 | NVCR | Burke William Patrick | CHRO | M - OptEx | $10.49 | +28.6K | 43.7K | +190% | +$300.0K |
| M | 2021-11-29 | 2021-11-26 | NVCR | Danziger Asaf | CEO, Dir | P - Purchase | $102.44 | +4,974 | 13.3K | +60% | +$509.5K |
| 2021-11-03 | 2021-11-02 | NVCR | Cordova Ashley | CFO | S - Sale | $107.28 | -209 | 41.8K | -0.5% | -$22.4K | |
| 2021-09-07 | 2021-09-02 | NVCR | Cordova Ashley | CFO | S - Sale | $138.23 | -828 | 42.0K | -2% | -$114.5K | |
| 2021-09-07 | 2021-09-02 | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $138.23 | -181 | 149.9K | -0.1% | -$25.0K | |
| M | 2021-09-07 | 2021-09-02+ | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale | $138.57 | -657 | 73.7K | -0.9% | -$91.0K |
| 2021-09-07 | 2021-09-02 | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $138.23 | -540 | 87.2K | -0.6% | -$74.6K | |
| DM | 2021-08-16 | 2021-08-12 | NVCR | Cordova Ashley | CFO | M - OptEx | $28.82 | +36.6K | 48.6K | +306% | +$1.06M |
| DM | 2021-08-16 | 2021-08-12 | NVCR | Cordova Ashley | CFO | S - Sale+OE | $140.94 | -26.6K | 46.0K | -37% | -$3.75M |
| D | 2021-08-16 | 2021-08-12 | NVCR | Cordova Ashley | CFO | G - Gift | $0.00 | -1,733 | 44.3K | -4% | $0 |
| 2021-08-06 | 2021-08-04 | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale | $148.71 | -2,063 | 74.2K | -3% | -$306.8K | |
| I | 2021-08-06 | 2021-08-05 | NVCR | Madden Martin J. | Dir | S - Sale | $153.13 | -34 | 384 | -8% | -$5,206 |
| D | 2021-08-06 | 2021-08-05 | NVCR | LEUNG GABRIEL | Dir | M - OptEx | $31.45 | +1,000 | 73.9K | +1% | +$31.4K |
| D | 2021-08-06 | 2021-08-05 | NVCR | LEUNG GABRIEL | Dir | S - Sale+OE | $152.50 | -1,000 | 72.9K | -1% | -$152.5K |
| M | 2021-08-04 | 2021-08-02+ | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $149.40 | -1,041 | 89.2K | -1% | -$155.5K |
| 2021-08-04 | 2021-08-03 | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale | $149.43 | -1,654 | 76.2K | -2% | -$247.2K | |
| 2021-08-04 | 2021-08-03 | NVCR | Benaim Ely | Chief Medical Off | S - Sale | $150.11 | -464 | 28.1K | -2% | -$69.7K | |
| 2021-08-04 | 2021-08-02 | NVCR | DOYLE WILLIAM F | Executive COB, Dir | S - Sale | $149.38 | -995 | 554.4K | -0.2% | -$148.6K | |
| D | 2021-08-03 | 2021-07-30 | NVCR | Benaim Ely | Chief Medical Off | M - OptEx | $83.30 | +651 | 29.8K | +2% | +$54.2K |
| DM | 2021-08-03 | 2021-07-30+ | NVCR | Benaim Ely | Chief Medical Off | S - Sale+OE | $154.63 | -1,187 | 28.6K | -4% | -$183.6K |
| 2021-07-08 | 2021-07-06 | NVCR | Benaim Ely | Chief Medical Off | A - Grant | $137.12 | +90 | 29.1K | +0.3% | +$12.3K | |
| 2021-07-08 | 2021-07-06 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $137.12 | +66 | 150.1K | +0.0% | +$9,050 | |
| 2021-07-08 | 2021-07-06 | NVCR | Cordova Ashley | CFO | A - Grant | $137.12 | +100 | 36.0K | +0.3% | +$13.7K | |
| 2021-07-08 | 2021-07-06 | NVCR | Leonard Frank X | Chief Development Off | A - Grant | $137.12 | +154 | 90.2K | +0.2% | +$21.1K | |
| 2021-07-08 | 2021-07-06 | NVCR | Weinberg Uri | CSO | A - Grant | $137.12 | +113 | 31.8K | +0.4% | +$15.5K | |
| D | 2021-07-08 | 2021-07-06 | NVCR | LEUNG GABRIEL | Dir | S - Sale+OE | $183.54 | -1,000 | 72.9K | -1% | -$183.5K |
| D | 2021-07-08 | 2021-07-06 | NVCR | LEUNG GABRIEL | Dir | M - OptEx | $31.45 | +1,000 | 73.9K | +1% | +$31.4K |
| 2021-07-08 | 2021-07-06 | NVCR | Longsworth Todd Christopher | GC | A - Grant | $137.12 | +154 | 67.9K | +0.2% | +$21.1K | |
| 2021-07-08 | 2021-07-06 | NVCR | Shah Pritesh | Chief Commercial Off | A - Grant | $137.12 | +154 | 77.9K | +0.2% | +$21.1K | |
| 2021-07-08 | 2021-07-06 | NVCR | Danziger Asaf | CEO, Dir | A - Grant | $137.12 | +118 | 8,302 | +1% | +$16.2K |
Purchase Sale Sale after option exercise All abbreviations